Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1539-1550

  Schiller, Brigitte ^a   Besarab, Anatole ^b  

^a CA   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Anemia; Chronic kidney disease; Efficiencies in care; Erythropoiesis stimulating agents

Indexed keywords

ANTIANEMIC AGENT; CTNO 528; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; HYPOXIA INDUCIBLE FACTOR INHIBITOR; PEGINESATIDE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TRANSCRIPTION FACTOR GATA; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; DRUG COST; DRUG HALF LIFE; GENE EXPRESSION; HEMODIALYSIS PATIENT; HUMAN; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANEMIA; CHRONIC DISEASE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MODELS, THEORETICAL; PATIENT CARE; RENAL DIALYSIS; TIME FACTORS;

EID: 79960431477     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.588202     Document Type: Review

References (89)

1. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 2. ESRD Incidence and Prevalence. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008:1-10. Available from http://www.usrds.org/adr-2008.htm [Last accessed 14 April 2011].
2. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Pré cis: An Introduction to ESRD in the U.S. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010:209-.
3. Available from http://www.usrds.org/atlas.htm [Last accessed 14 April 2011].
4. United States Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 2. ESRD Incidence and Prevalence. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007:81-98. Available from http://www.usrds.org/adr.htm [Last accessed 7 November 2007].
5. Ulrich B. An ANNA invitational summit: nephrology nursing shortage and solutions. Nephrol Nurs J 2003;30:360-3.
6. Rosenberg ME. Adult nephrology fellowship training in the United States: trends and issues. J Am Soc Nephrol 2007;18:1027-33. (Pubitemid 46536888)
7. Council on Physician and Nurse Supply. CPNS Press releases and news coverage [press release]. 2009.
8. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481-8. (Pubitemid 41208184)
9. Di Iorio B, Cirillo M, Bellizzi V, et al. Prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients-the Campania Dialysis Registry. Int J Artif Organs 2007;30:325-33. (Pubitemid 46938857)
10. Basile JN. Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease. South Med J 2007;100:1200-7. (Pubitemid 350304825)
11. Muzzarelli S, Pfisterer M, for the TIME Investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006;152:991-6. (Pubitemid 44632950)
12. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-91.
13. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Primary Care 2008;35:329-44. (Pubitemid 351680117)
14. Charytan C. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. Clin J Am Soc Nephrol 2010;5:2355-62.
15. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3:200-7.
16. Jones M, Ibels L, Schenkel B, et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004;65:757-67. (Pubitemid 38251052)
17. Chan K, Moran J, Hlatky M, et al. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 2009;24:1956-62.
18. Chan KE, Lafayette RA, Whittemore AS, et al. Facility factors dominate the ability to achieve target hemoglobin levels in hemodialysis patients. Nephrol Dial Transplant 2008;23:2948-56.
19. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 5. Clinical Indicators and Preventative Health. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011:260-9. Available from http://www.usrds.org/atlas.htm [Last accessed 14 April 2011].
20. Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003;64:1514-21. (Pubitemid 37153820)
21. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43. (Pubitemid 43246455)
22. Walker R, Pussell BA, on behalf of the Australian Renal Anemia Group. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. Nephrology 2007; 12:448-51. (Pubitemid 47366636)
23. Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-70. (Pubitemid 350223976)
24. Eckardt KU, Kim J, Kronenberg F, et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010; 21:1765-75.
25. Weinhandl ED, Peng Y, Gilbertson DT, et al. Hemoglobin variability and mortality: confounding by disease severity. Am J Kidney Dis 2011;57:255-65.
26. Pisoni RL, Bragg-Gresham JL, Fuller DS, et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 2011; 57:266-75.
27. Wish JB. Hemoglobin variability as a predictor of mortality: what's a practitioner to do? Am J Kidney Dis 2011;57:190-3.
28. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007;50:989-1000. (Pubitemid 350122810)
29. Levin NW, Fishbane S, Canedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21. (Pubitemid 47576167)
30. Wish JB. Past, present, and future of chronic kidney disease anemia management in the United States. Adv Chronic Kidney Dis 2009;16:101-8.
31. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
32. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-84. (Pubitemid 44749316)
33. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
34. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98. (Pubitemid 44749317)
35. Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis 2009;16:131-42.
36. Coyne DW, Brennan DC. Seeking safe and efficacious anemia management. Semin Dial 2009;22:590-1.
37. Brophy DF, Daniel G, Gitlin M, et al. Characterizing hospitalizations of endstage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy. Ann Pharmacother 2010;44:43-9.
38. Solid CA, Foley RN, Gilbertson DT, et al. Perihospitalization hemoglobinepoetin associations in U.S. hemodialysis patients, 1998 to 2003. Hemodial Int 2007;11:442-7. (Pubitemid 47534870)
39. Chan KE, Lazarus JM, Wingard RL, et al. Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. Kidney Int 2009;76:331-41.
40. Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 2005;15:245-50. (Pubitemid 41022626)
41. Rice L, Alfrey CP, Driscoll T, et al. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 1999;33:59-62. (Pubitemid 29031209)
42. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2:1405-16.
43. Besarab A. Optimizing anaemia management with subcutaneous administration of epoetin. Nephrol Dial Transplant 2005;20(Suppl 6):vi10-15.
44. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339:578-83. (Pubitemid 28385654)
45. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesisstimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant 2007;22(Suppl 4):iv19-30.
46. Jadoul M, Vanrenterghem Y, Foret M, et al. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004;19:898-903. (Pubitemid 38455662)
47. Trachsler J, Gluck Z, Dickenmann M, et al. Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis. Clin Nephrol 2009;71:697-702.
48. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010;25:4009-17.
49. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006;19:1-4. (Pubitemid 43479005)
50. Spinowitz B, Germain M, Benz R, et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1015-21.
51. Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44:866-76. (Pubitemid 39445919)
52. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-15.
53. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46.
54. Choi P, Dalby E, Watson T, et al. Conversion of hemodialysis patients from weekly IV darbepoietin to monthly IV CERA results in less effective maintenance of hemoglobin level and increased transfusion requirement [abstract]. J Am Soc Nephrol 2009;20:663A.
55. Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007;23:969-79. (Pubitemid 46799579)
56. Mircera-(Methoxy Polyethylene Glycol-Epoetin Beta) Continuous Activity. Targeted Stability [monograph], 2009:1-47.
57. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11. (Pubitemid 44389891)
58. Green JM, Mortensen RB, Schatz PJ, et al. HematideTM demonstrates prolonged in vitro binding to the human erythropoietin receptor (ASN abstract SAPO2430). J Am Soc Nephrol 2009;20:668A.
59. Schiller B, Locatelli F, Covic AC, et al. Primary results from two phase 3 randomized, active-controlled, open-label studies (EMERALD 1 and EMERALD 2) of the safety and efficacy of HematideTM/peginesatide for the maintenance treatment of anemia in patients with chronic renal failure who were receiving hemodialysis and were previously treated with epoetin alfa or epoetin beta. Am J Nephrol 2010;21:2b.
60. Saueressig U, Kwan JTC, De Cock E, et al. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif 2008; 26:537-46.
61. Schiller B, Doss S, De Cock E, et al. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Hemodial Int 2008;12:441-9.
62. Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 2010;75:49029-214.
63. Lee DE, Son W, Ha BJ, et al. The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun 2006; 339:380-5. (Pubitemid 41697561)
64. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007;110:2140-7. (Pubitemid 47443933)
65. Mikhail A, Covic A, Goldsmith D. Stimulating erythropoiesis: future perspectives. Kidney Blood Press Res 2008;31:234-46.
66. Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008; 48:1197-207.
67. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21:2151-6.
68. Besarab A, Hulter HN, Klaus S, et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract]. J Am Soc Nephrol 2011;21:95A.
69. Brigandi RA, Russ SF, Al-Banna M, et al. Prolylhydroxylase inhibitor modulation of erythropoietin in a randomized placebo controlled trial [abstract]. J Am Soc Nephrol 2011;21:390A.
70. Nakano Y, Imagawa S, Matsumoto K, et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 2004;104:4300-7. (Pubitemid 39620186)
71. Akagi S, Ichikawa H, Okada T, et al. The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J Am Soc Nephrol 2004;15:3215-24. (Pubitemid 39578854)
72. Gagnon L, Brabe J, Penney C, et al. Oral treatment with PBI-1402 increases hemoglobin level and red blood cell count: A novel approach to treating chemotherapy-induced anemia. Blood 2007;110:2211.
73. Gagnon L, Leblond FA, Grouix B, et al. Oral treatment with PBI-1402 increases hemoglobin, hematocrit and red blood cell formation in 5/6-nephrectomized rats, a model mimicking human end-stage renal disease [poster]. J Am Soc Nephrol 2009;20:666A.
74. Perez-Garcia R, Martin-Malo A, Fort J, et al. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER-a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 2009;24:578-88.
75. Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007;18:2377-84. (Pubitemid 47203853)
76. Foley RN, Hakim RM. Why is the mortality of dialysis patients in the United States much higher than the rest of the world? J Am Soc Nephrol 2009; 20:1432-5.
77. Yaqub MS, Leiser J, Molitoris BA. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 2001;21:390-6. (Pubitemid 34701846)
78. Parker III TF, Glassock RJ, Steinman TI. Conclusions, consensus, and directions for the future. Clin J Am Soc Nephrol 2009;4(Suppl 1):S139-44.
79. Mircescu G, Garneata L, Ciocalteu A, et al. Once-every-2-weeks and onceweekly epoetin beta regimens: equivalency in hemodialyzed patients. Am J Kidney Dis 2006;48:445-55. (Pubitemid 44262436)
80. de Francisco ALM, Sulowicz W, Klinger M, et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006; 60:1687-96. (Pubitemid 44742173)
81. Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010;26:1083-9.
82. Weinreich T, Leistikow F, Hartmann HG, et al. Once monthly C.E.R.A. in hemodialysis patients provides stable Hb levels-results from the non-interventional SESAM study. Presented at: 48th Annual Congress of the European Renal Association and European Dialysis and Transplantation Association; 25-28 June 2010; Munich, Germany.
83. Meier P, Meier R. Efficacy of intravenous CERA administered once monthly on haemoglobin levels compared with epoetin beta administered once weekly in patients with end-stage kidney disease on hemodialysis: a randomized trial [abstract]. NDT Plus 2009;2(Suppl 2).
84. Ponikvar R, Blanusa D, Ceglar Z, et al. Once monthly C.E.R.A. in unselected chronic hemodialysis patients following direct switch from shorter acting ESA's [abstract]. NDT Plus 2009;19(Suppl 2).
85. Iatrou CE. Once-monthly continuous erythropoietin receptor activator (C.E.R.A.) chronic renal anemia on hemodialysis [abstract]. J Am Soc Nephrol 2009;20:663A.
86. Schuster SJ, Caro J. Erythropoietin: physiologic basis for clinical applications. Vox Sang 1993;65:169-79. (Pubitemid 23291051)
87. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-30. (Pubitemid 27157944)
88. Papayannopoulou T, D'Andrea AD, Abkowitz JL, et al. Biology of erythropoiesis, erythroid differentiation, and maturation. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice, 4th edn. Philadelphia: Elsevier Churchill Livingstone, 2005:267-88.
89. Hillman RS, Finch CA. General characteristics of the erythron. In: Hillman RS, Finch CA, eds. Red Cell Manual, 7th edn. Philadelphia: F.A. Davis Company, 1996:1-38